An investigation of the pharmacokinetics of topical Lamisil® 1% cream
- Authors: Hill S, Thomas R, Smith S, Finlay A, Hill S1, Thomas R1, Smith S2, Finlay A1
-
Affiliations:
- University of Wales College of Medicine
- Sandoz Products Limited, Frimley Business Park
- Issue: Vol 87, No 3 (2011)
- Pages: 120-125
- Section: Articles
- URL: https://journals.rcsi.science/0042-4609/article/view/117442
- DOI: https://doi.org/10.25208/vdv1036
- ID: 117442
Cite item
Full Text
Abstract
randomized to receive Lamisil® 1% cream applied to the skin on the back on 1 day, or on 3, 5 or 7 consecutive days.
Up to five biopsies were taken at a site on the upper back at various time-points both during treatment and after
treatment. Lamisil® levels in the biopsies were analyzed using HPLC.
The study showed that increasing the number of applications from one to seven did not significantly increase the peak
concentration (Cmax) in the stratum corneum.
However, there was an increase in the total amount of Lamisil® found in the stratum corneum resulting in Lamisil® being
detected for longer periods after cessation of therapy.
Treatment for 7 days resulted in Lamisil® still being detectable 7 days after cessation of therapy, and the drug
concentration was significantly higher than the concentration killing the common causative organisms of superficial
dermatomycoses.
This study indicates a significant potential for short-term treatment with Lamisil® 1% cream in superficial
dermatomycoses.
About the authors
S Hill
R Thomas
S Smith
A Finlay
S Hill
University of Wales College of Medicine; University of Wales College of Medicine
R Thomas
University of Wales College of Medicine; University of Wales College of Medicine
S Smith
Sandoz Products Limited, Frimley Business Park; Sandoz Products Limited, Frimley Business Park
A Finlay
University of Wales College of Medicine; University of Wales College of Medicine
References
- Petranyi G., Meingassner J.G. Mieth H. Antifungal activity of the allylamine derivative terbinafine in vitro. Ancimicrob Agents Chemother 1987: 31: 1365-8.
- Clayton Y.M. In vitro activity of terbinifine. Clin Exp Dermatol 1989: 14: 101-3.
- Villars V., Jones TC. Clinical efficacy and tolerabiiity of terbinafine (Lamisil) - a new topical and systemic fungicidal drug for treatment of dermatomycoses. Clin Exp Dermal 1989; 14: 124-7.
- Smith E.S., Zaias N., Savin R. Topical terbinafime in tinea pedis. J Clin Pharmacol 1987: 27: 720. Литература
- Jones T.C., Villars V. Terbinafine. In: Chemotherapy antifungal Diseases (Handbook of Experimental Pharmacology, Vol. 96) (Ryley J.F., ed.). Benin: Springer-Verlag, 1990: 483-501.
- Evans E.G.V., James I.G.V., Joshipura R.C. Two-week treatment of tinea pedis with terbinafine (Lamisil) 1% cream: a placebo-controlled study. J Dermatol Treat 1990: 2: 95-7.
- Zaias N. The еffiасу of 1% terbinafine cream in cutaneous candidiasis and tinea corporis/cruris once a day applications for one week (a doubleblind study comparing active cream to vehicle cream). In: Clinical Dermalalogy in the Year 2000 (programme and abstracts of symposium. London, 22-25 May 1990) (Greaves M.W., ed.). London: COT Presentations, 1990: 53.
- Marks R., Dawber R.P.R. Skin surface biopsy: an improved technique for the examination of the horny layer. Br J Dermatol 1971: 84: 117-23.
- Watson W.S., Finlay A.Y. The effect of the vehicle formulation on the stratum corneum penetration characteristics of clobetasol 17-propionate in vivo. Br J Dermatol 1999: 118: 523-30.
Supplementary files
